ISIS 2302 antisense inhibitor of ICAM-1 data
ISIP announced positive results of a Phase II trial of ISIS 2302. Based on these results, ISIP and partner Boehringer Ingelheim plan to begin a Phase III trial in April.
Trends in the three indices favored the treatment groups. At the end of one month of therapy, 47 percent of treated patients were in remission